Lifevantage (NASDAQ:LFVN) reported a 22% decline in revenue for its fiscal first quarter and outlined a strategy to overhaul its brand, digital sales tools and cost structure as it works to stabilize the business.
Revenue for the quarter ended September 30, 2026, fell to $37.1 million from $47.6 million a year earlier. The company posted a net loss of $0.2 million, or $0.02 per diluted share, compared with net income of $2.2 million, or $0.17 per diluted share, in the prior-year period.
Lower Orders Weigh on Results
Chief Financial Officer Carl Aure said the revenue decline reflected fewer orders from active consumers and smaller average orders, as well as lower sales of the MindBody GLP-1 System. Sales from the LoveBiome product line, acquired in October 2025, partly offset those declines.
Revenue fell 22.2% to $29 million in the Americas and 21.2% to $8.2 million in Asia-Pacific and Europe. Foreign currency movements reduced total revenue by $0.4 million, Aure said. Subscription-based revenue accounted for more than 75% of the quarterly total, and retention metrics for both consultants and customers improved from a year earlier.
Gross margin declined to 75.4% from 79.5%, reflecting higher inventory obsolescence, shipping and warehouse expenses. Excluding an additional inventory allowance related to MindBody, adjusted gross margin was 78.2%.
Adjusted earnings before interest, taxes, depreciation and amortization fell to $1.9 million, or 5.2% of revenue, from $3.9 million, or 8.2% of revenue, a year earlier. Adjusted net income was $0.6 million, or $0.05 per diluted share, compared with $2.3 million, or $0.18 per diluted share.
Brand and Digital Plans
Moorehead said the strategy has three components: repositioning LifeVantage as a next-generation nutraceutical company, simplifying its consumer and selling proposition, and focusing investment on selected markets and growth opportunities.
The company is launching a campaign for its Protandim Nrf2 product. Moorehead said it will draw on research concerning the product’s effect on cells exposed to environmental toxins. The campaign will initially reach the company’s distributor base and use an email list of more than half a million names, with a broader digital campaign to follow in the new year.
LifeVantage plans to launch a new website and digital platform in North America in the second quarter of calendar 2027, followed by a seller business suite in the third quarter. Moorehead described the suite as a toolkit for customer relationship management, email and text outreach, social media, marketing and training. He said artificial intelligence support and coaching tools could follow in 12 to 18 months.
Management is also reviewing selling, general and administrative spending. Moorehead said the company expects to reallocate resources to improve efficiency and fund reinvestment for growth, while development of the new tools will be capital spending.
Cash, Spending and Fiscal-Year Change
LifeVantage ended September with $13.7 million in cash and no debt, compared with $14.9 million in cash at June 30. It generated $0.5 million in operating cash flow during the quarter and had no outstanding balance on its $5 million revolving credit line.
Capital expenditures rose to $1.2 million from $0.4 million a year earlier, largely because of technology investments. Aure said spending could remain around $1 million a quarter for the next couple of quarters before easing, with annualized spending of approximately $3 million to $3.5 million while the e-commerce platform and business suite are being developed.
The company did not repurchase shares during the quarter and had $58.5 million remaining under its $60 million authorization. It also announced a $0.05-per-share quarterly cash dividend, payable December 15 to shareholders of record December 1, 2026.
LifeVantage is changing its fiscal year to align with the calendar year beginning January 1, 2027. It plans to file a Form 10-KT with audited financial statements for the six-month transition period ending December 31, 2026, in the first quarter of calendar 2027. The company did not issue formal guidance, citing the CEO transition and fiscal-year change.
About Lifevantage (NASDAQ:LFVN)
LifeVantage Corporation is a health and wellness company that develops, markets and distributes dietary supplements and personal-care products. Its product portfolio is designed to support areas such as cellular health, antioxidant defenses, energy, nutrition and skin care.
The company’s principal brands have included Protandim, a line of dietary supplements; TrueScience, a skin-care and wellness brand; and Petandim, products formulated for pets. LifeVantage primarily uses a direct-selling business model, distributing its products through independent sales representatives and online channels.
Founded in 2003 and headquartered in Lehi, Utah, LifeVantage serves customers in the United States and selected international markets.
